The Clinical Studies Committee (CSC) of Drug Regulatory Authority of Pakistan (DRAP) is mandated under Bio Study Rules 2017 for the regulatory oversight of clinical trials and clinical studies related to therapeutic goods in the country. The CSC reviews and approves clinical study protocols, ensuring they adhere to ethical and scientific standards. It also monitors ongoing clinical trials to assess participant safety and efficacy, makes informed decisions regarding study design, and collaborates with researchers, sponsors, and other stakeholders to ensure quality clinical research and safety of the participants.
The Committee has decided that the CSC meetings will be convened after every 45 days and an annual CSC meeting schedule for 2025 (tentative) has been issued with the aims to enhance transparency, efficiency, and collaboration.
| S. No. | CSC Meeting | Proposed Date |
| 01 | 54th CSC Meeting | 28th – 31st January 2025 |
| 02 | 55th CSC Meeting | 03rd – 08th March 2025 |
| 03 | 56th CSC Meeting | 21st – 25th April 2025 |
| 04 | 57th CSC Meeting | 26th – 31st May 2025 |
| 05 | 58th CSC Meeting | 07th – 11th July 2025 |
| 06 | 59th CSC Meeting | 25th – 29th August 2025 |
| 07 | 60th CSC Meeting | 01st – 03rd October 2025 |
| 08 | 61st CSC Meeting | 08th – 12th December 2025 |